



4 November 2021

Creso Pharma appoints Hon. Dr Brian Walker MLC as strategic consultant and chair to newly established Scientific Advisory Committee

Highlights:

- Hon. Dr Walker MLC is a politician and medical practitioner involved in advocating for the legalisation and use of medicinal cannabis and psychedelics
- Elected to the Western Australian Legislative Council as a Legalise Cannabis WA member for the East Metropolitan Region – term commenced 24 May 2021
- Dr Walker is a board member of Mind Medicine Australia, a not-for-profit, peak body group aimed at the legislation, access and treatment of psychedelics products
- Creso Pharma is confident that Dr Walker's appointment will provide further access to additional opportunities with other peak bodies and industry participants
- Formation of the Scientific Advisory Committee to significantly accelerate R&D initiatives and product development
- Additional appointments pending – discussions with local and international industry leaders well progressed
- The formation of the committee will aim to strengthen Creso's scientific and evidence-based approach to product development
- Benefits to span across all divisions including Swiss operations, Mernova Medicinal Inc. and Halucenex Life Sciences Inc.
- Initiative is anticipated to add to the growing body of evidence for Creso Pharma's large portfolio of hemp-derived CBD, cannabis and psychedelic products
- The committee will be instrumental in developing R&D trials and ongoing product development for Creso Pharma's imminent scale up in the US market
- The Committee will oversee potential future R&D initiatives intended to provide Creso Pharma with another building block ahead of its proposed NASDAQ dual listing
- Board, management team and advisors to leverage extensive industry experience to drive value for shareholders

Creso Pharma Limited (ASX:CPH, OTC:COPHF, FRA:1X8) ('Creso Pharma' or 'the Company') is pleased to advise that it has increased its R&D and management capacity following the appointment Dr Brian Walker as a strategic consultant to the Company and chair to the newly created Scientific Advisory Committee ("Committee").

Dr Brian Walker is a politician and medical practitioner who has a long-standing commitment to cannabis legalisation and holistic wellness. At the 2021 Western Australian state election, Dr Walker was elected to the Western Australian Legislative Council as a Legalise Cannabis WA member for the East Metropolitan Region. He is also a board member of not-for-profit group, Mind Medicines Australia, the peak body focused on expanding treatment options available to medical practitioners through the use of psychedelic-assisted treatments.



In his role as a strategic consultant, Dr Walker will oversee and provide input into the Company's medicinal cannabis, hemp and psychedelic products. This includes but is not limited to reviewing and providing input on all the scientific documents related to the research and technical operations of the Company, advising the Board on new scientific developments and commercial opportunities that could support the success of Creso Pharma and evaluating potential R&D and scientific projects for the Company to participate in. As part of his remuneration package, the Company will issue 200,000 options to Brian Walker (or his nominee) per the Appendix 3B released today.

As a result of Mr Walker's position as a board member of Mind Medicine Australia and through the other roles that he has held over his esteemed career, Creso Pharma is also confident that Dr Walker's appointment will provide the Company with additional access to opportunities, including local and international peak bodies and industry participants. Creso Pharma will leverage his established network to progress a number of near term opportunities.

As part of his appointment, Dr Walker will also act as the chair for the newly established Scientific Advisory Committee. The Committee is expected to significantly expand Creso Pharma's pharmaceutical expertise in all applied science activities. The benefits will extend across all operating divisions of the Company and will substantially increase the scope of work and fast track the current pipeline of product development and R&D initiatives.

It highlights the scientific and evidence-based approach Creso Pharma takes during the product development of all medicinal cannabis, hemp-based and psychedelics products. The Committee will add another level of oversight to this process.

The development provides a major opportunity for Creso Pharma to further accelerate R&D, product development and other clinical trials ahead of its rapid trajectory into the US market and potential NASDAQ listing. The Company is currently in discussions with a number of industry leaders that have been earmarked for positions on the new Committee.

The establishment of the Committee significantly strengthens the Company's management team. Creso Pharma has a number of near term opportunities in train and will leverage the extensive scientific industry expertise of Dr Walker and the Committee to unlock value for shareholders.

Commentary:

Non-executive Chairman, Mr Adam Blumenthal said: *"We are very pleased to welcome Dr Brian Walker to Creso Pharma as a strategic advisor as well as the chair to our new Scientific Advisory Committee.*

"Brian's passion and knowledge on the scientific and pharmaceutical advantages of cannabis and hemp products will assist us in a number of efforts, including R&D, product development and access to a range of other specialists and industry leaders to round out the Committee.

"We look forward to additional Committee appointments with both local and international specialists, particularly as we scale up our product offering and progress work towards clinical trials. The Company looks forward to working with Brian and leveraging his experience to unlock value for our shareholders."

Hon. Dr Brian Walker MLC, added: *"I am honoured to be appointed as a consultant to Creso Pharma, and as the inaugural Chair of the Company's Scientific Advisory Committee. Over the course of my career, I have always advocated for the use of medicinal cannabis and psychedelics as alternative treatments and this role will provide another avenue to broaden awareness of their benefits.*



"Initially, my focus will be on appointing additional industry participants to join the Committee, while pursuing potential trials, grants and opportunities which will highlight Creso Pharma's leading products and potential in these growing subsectors of the medical field."

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Board of Directors of Creso Pharma Limited.

For further information, please contact:

Investor Enquiries

Creso Pharma Limited
E: info@cresopharma.com
P: +61 (0) 497 571 532

Enquiries can be texted to +61 (0) 497 571 532

Released through:

Ben Jarvis, Six Degrees Investor Relations: Ph: +61 (0) 413 150 448

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Creso Pharma offices:

Australia

Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Switzerland

Allmendstrasse 11, 6310 Steinhausen, Schweiz

Canada

59 Payzant Driver, Windsor, Nova Scotia, B0N 2T0



Canada

50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.